{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:31Z","timestamp":1790931331953,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Since 2019, EAU guidelines recommend PSMA-PET\/CT for staging high-risk prostate cancer. However, real-world data on its uptake and association with disease characteristics and outcomes in metastatic castration-sensitive prostate cancer (mCSPC) remains limited. We evaluated real-world PSMA-PET\/CT use versus conventional imaging (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 3,644 mCSPC patients (2016\u20132021) from 19 hospitals in the Dutch CAPRI-3 registry. Staging within 90\u00a0days of diagnosis was classified as CI-only (CT, bone scintigraphy, and\/or MRI) or PSMA-PET (\u00b1\u2009CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most patients were staged with CI-only (63%), but PSMA-PET use rose from 8% in 2016 to 62% in 2021. PSMA-PET-staged patients were younger (72 vs. 76\u00a0years) and had significantly lower tumour burden (27% vs. 45% high-volume), more nodal-only disease, and were more likely to have metachronous presentation (29% vs. 22%, all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In the PSMA-PET group, 42% received ADT plus targeted therapy and 23% ADT monotherapy (vs. 45% ADT monotherapy in CI-only). Median overall survival was significantly longer in the PSMA-PET cohort (78.3 vs. 40.0\u00a0months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There has been an increasing trend toward the use of PSMA PET\/CT for staging mCSPC in recent years, identifying a population with more favourable disease characteristics and a more favourable prognosis. This shift in patient characteristics, driven by stage migration (the Will Rogers phenomenon), influences clinical management by enabling more refined patient selection for conservative or targeted therapies. Consequently, accounting for lead-time and selection bias is essential when comparing survival outcomes in the PSMA PET\/CT era.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08050-7","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:11:29Z","timestamp":1783653089000},"page":"7017-7027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9986-2416","authenticated-orcid":false,"given":"K. J. M.","family":"van der Velden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C. M.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"van der Doelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lavalaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tascilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A. Uyl-de","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. P.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"10231","key":"8050_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"6","key":"8050_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, et al. Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786\u201393.","journal-title":"J Nucl Med"},{"issue":"5","key":"8050_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s00259-019-4258-6","volume":"46","author":"A Heinzel","year":"2019","unstructured":"Heinzel A, et al. (68)Ga-PSMA PET\/CT for monitoring response to (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1054\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"8050_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403\u201317.","journal-title":"Eur Urol"},{"issue":"12","key":"8050_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","volume":"62","author":"F Barbato","year":"2021","unstructured":"Barbato F, et al. PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J Nucl Med. 2021;62(12):1747\u201350.","journal-title":"J Nucl Med"},{"issue":"1","key":"8050_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2967\/jnumed.124.268441","volume":"66","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, et al. Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET-an international multicenter retrospective study. J Nucl Med. 2025;66(1):54\u201360.","journal-title":"J Nucl Med"},{"issue":"8","key":"8050_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/ph14080713","volume":"14","author":"U Hennrich","year":"2021","unstructured":"Hennrich U, Eder M. [(68)Ga]Ga-PSMA-11: The first FDA-approved (68)Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14(8):713.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"8050_CR8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62(5):596\u2013604.","journal-title":"J Nucl Med"},{"issue":"17","key":"8050_CR9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.19.02757","volume":"38","author":"EJ Trabulsi","year":"2020","unstructured":"Trabulsi EJ, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol. 2020;38(17):1963\u201396.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8050_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2020","unstructured":"Cornford P, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2020;79(2):263\u201382.","journal-title":"Eur Urol"},{"issue":"2","key":"8050_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, et al. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8050_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","volume":"74","author":"S Han","year":"2018","unstructured":"Han S, et al. Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018;74(2):179\u201390.","journal-title":"Eur Urol"},{"issue":"1","key":"8050_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.euo.2023.06.002","volume":"7","author":"A Sood","year":"2024","unstructured":"Sood A, et al. The impact of positron emission tomography imaging and tumor molecular profiling on risk stratification, treatment choice, and oncological outcomes of patients with primary or relapsed prostate cancer: an international collaborative review of the existing literature. Eur Urol Oncol. 2024;7(1):27\u201343.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"8050_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.euf.2016.09.008","volume":"4","author":"HM Westgeest","year":"2018","unstructured":"Westgeest HM, et al. Differences in trial and real-world populations in the Dutch castration-resistant prostate cancer registry. Eur Urol Focus. 2018;4(5):694\u2013701.","journal-title":"Eur Urol Focus"},{"key":"8050_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153808","author":"D Bosch","year":"2023","unstructured":"Bosch D, et al. Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry driven by artificial intelligence. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153808.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"8050_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"2","key":"8050_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"11","key":"8050_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8050_CR19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2967\/jnumed.121.263556","volume":"63","author":"NC Friedman","year":"2022","unstructured":"Friedman NC, Hines E Jr. The Will Rogers phenomenon and PSMA PET\/CT. J Nucl Med. 2022;63(6):966.","journal-title":"J Nucl Med"},{"issue":"25","key":"8050_CR20","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","volume":"312","author":"AR Feinstein","year":"1985","unstructured":"Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312(25):1604\u20138.","journal-title":"N Engl J Med"},{"key":"8050_CR21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.271598","author":"LM Unterrainer","year":"2026","unstructured":"Unterrainer LM, et al. Prognostic value of PSMA PET-derived tumor burden stratification in metastatic hormone-sensitive prostate cancer. J Nucl Med. 2026. https:\/\/doi.org\/10.2967\/jnumed.125.271598.","journal-title":"J Nucl Med"},{"issue":"16_suppl","key":"8050_CR22","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1200\/JCO.2025.43.16_suppl.5091","volume":"43","author":"Z Sabahi","year":"2025","unstructured":"Sabahi Z, et al. Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort. J Clin Oncol. 2025;43(16_suppl):5091\u20135091.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8050_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003998","volume":"19","author":"CC Parker","year":"2022","unstructured":"Parker CC, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19(6):e1003998.","journal-title":"PLoS Med"},{"issue":"4","key":"8050_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali A, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7(4):555\u201363.","journal-title":"JAMA Oncol"},{"issue":"10","key":"8050_CR25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024;25(10):1267\u201376.","journal-title":"Lancet Oncol"},{"issue":"16_sippl","key":"8050_CR26","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1200\/JCO.2025.43.16_suppl.5009","volume":"43","author":"BM Priv\u00e9","year":"2025","unstructured":"Priv\u00e9 BM, et al. Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (BULLSEYE trial). J Clin Oncol. 2025;43(16_sippl):5009\u20135009.","journal-title":"J Clin Oncol"},{"issue":"27","key":"8050_CR27","doi-asserted-by":"publisher","first-page":"44131","DOI":"10.18632\/oncotarget.17311","volume":"8","author":"V Wenter","year":"2017","unstructured":"Wenter V, et al. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget. 2017;8(27):44131\u201340.","journal-title":"Oncotarget"},{"issue":"3","key":"8050_CR28","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/bju.16577","volume":"135","author":"AD Raval","year":"2025","unstructured":"Raval AD, et al. Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU Int. 2025;135(3):408\u201321.","journal-title":"BJU Int"},{"issue":"4","key":"8050_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"issue":"5","key":"8050_CR30","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.euo.2025.08.007","volume":"8","author":"R Nicoletti","year":"2025","unstructured":"Nicoletti R, et al. Treatment trajectories in metastatic hormone-sensitive prostate cancer: A PIONEER+ big data analysis. Eur Urol Oncol. 2025;8(5):1340\u20139.","journal-title":"Eur Urol Oncol"},{"key":"8050_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.10.020","volume":"47","author":"F Saad","year":"2023","unstructured":"Saad F. Debate on treating oligometastatic metastatic hormone-sensitive prostate cancer: the argument for new-generation hormone therapy and radiation therapy to the prostate. Eur Urol Open Sci. 2023;47:1\u20132.","journal-title":"Eur Urol Open Sci"},{"key":"8050_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244263","volume":"16","author":"F von Stauffenberg","year":"2024","unstructured":"von Stauffenberg F, et al. Current clinical applications of PSMA-PET for prostate cancer diagnosis, staging, and treatment. Cancers. 2024;16:4263. https:\/\/doi.org\/10.3390\/cancers16244263.","journal-title":"Cancers"},{"issue":"1","key":"8050_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102476","volume":"24","author":"W Issa","year":"2026","unstructured":"Issa W, et al. Real-world treatment outcomes in patients with Ga68-PSMA-PET positive metastatic hormone-sensitive prostate cancer with or without conventional imaging correlates. Clin Genitourin Cancer. 2026;24(1):102476.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"8050_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, et al. PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open. 2025;8(1):e2452971.","journal-title":"JAMA Netw Open"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08050-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08050-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08050-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:31:56Z","timestamp":1790929916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08050-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8050"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08050-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Medical Research Ethics Committee Oost-Nederland, CMO 2020\u20136573) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":1,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all living subjects included in the study. In accordance with national guidelines and the approval of the Medical Research Ethics Committee, individual informed consent was not required for patients who were deceased or lost to follow-up at the time of data collection, provided that no prior objection was registered.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB, MvdD, AvdE, RvM, DS, CUdG, MK, and IO have received grants, honoraria, or participated in advisory roles for Bayer, Astellas, Janssen, and others (full details available upon request). KV has received honoraria from Bayer. DB has received honoraria from MSD. The remaining authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosure of potential conflicts of interest.","order":4,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}